Basic and clinical studies of pazufloxacin in respiratory infections

DOI 5 References
  • Gaja Michihiro
    First Department of Internal Medicine, School of Medicine, University of the Ryukyus
  • Tateyama Masao
    First Department of Internal Medicine, School of Medicine, University of the Ryukyus
  • Inadome Jun
    First Department of Internal Medicine, School of Medicine, University of the Ryukyus
  • Fukuhara Hiroshi
    First Department of Internal Medicine, School of Medicine, University of the Ryukyus
  • Saito Atsushi
    First Department of Internal Medicine, School of Medicine, University of the Ryukyus
  • Kusano Nobuchika
    Central Clinical Laboratory, University of the Ryukyus

Bibliographic Information

Other Title
  • 呼吸器感染症に対するpazufloxacinの基礎的ならびに臨床的検討

Search this article

Abstract

We performed a basic evaluation of pazufloxacin (PZFX), a newly developed new quinolone agent, and clinically studied its application in the treatment of respiratory infections, with the following results.<BR>1. Antibacterial activity<BR>The minimum inhibitory concentrations (MICs) of PZFX against 272 strains of 12 species isolated from clinical material were measured and compared with those of other new quinolone agents, ofloxacin (OFLX), tosufloxacin (TFLX) and ciprofloxacin (CPFX). The antimicrobial activity of PZFX for grampositive coccus was the same as that of OFLX and for gram-negative rod was slightly better than those of TFLX and CPFX.<BR>2. Clinical efficacy<BR>Ten patients with respiratory tract infections were given PZFX for 4 to 15 days. Clinical efficacy was assessed as good in 9 cases and poor in 1 case. No side effects were observed.

Journal

References(5)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top